8 completed, 4 terminated, 1 active not recruiting, 1 not yet recruiting. 10 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Terminated 2, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 3 | Terminated 2, Active not recruiting 1 |
Follow vTv Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems Cadisegliatin 800 mg QD, Placebo - Type 1 Diabetes (T1D) | Phase 2 | Not yet recruiting | vTv Therapeutics | 40 | 2026-10-01 | 2026-09-21 |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo - Diabetes Mellitus, Type 1 | Phase 3 | Active not recruiting | vTv Therapeutics | 150 | 2024-06-14 | 2026-07-28 |
| Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance Azeliragon, Placebo - Alzheimer Disease | Phase 2 | Terminated | vTv Therapeutics | 43 | 2019-06-27 | 2022-01-21 |
| Evaluation of TTP399 in Patients With Type 1 Diabetes TTP399, Placebo Oral Tablet - Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Completed | vTv Therapeutics | 115 | 2017-10-25 | 2023-07-03 |
| 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) Azeliragon 5mg - Alzheimer's Disease | Phase 3 | Terminated | vTv Therapeutics | 297 | 2016-12-01 | 2021-06-01 |
| A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes TTP273, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | vTv Therapeutics | 174 | 2015-12-01 | 2017-02-10 |
| Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Azeliragon, Placebo - Alzheimer's Disease | Phase 3 | Terminated | vTv Therapeutics | 880 | 2015-04-01 | 2021-05-07 |
| Add Glucokinase Activator to Target A1c TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg - Diabetes Mellitus, Type 2 | Phase 2 | Completed | vTv Therapeutics | 190 | 2015-03-01 | 2017-02-10 |
| A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes TTP054, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | vTv Therapeutics | 186 | 2012-08-01 | 2017-02-10 |
| A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes GK1-399 (formerly TTP399), Placebo - Type 2 Diabetes Mellitus | Phase 1 / Phase 2 | Completed | vTv Therapeutics | 248 | 2011-11-01 | 2013-09-13 |
| A Safety Study of TTP4000 in Subjects With Alzheimer's Disease TTP4000, Placebo - Alzheimer's Disease | Phase 1 | Completed | vTv Therapeutics | 8 | 2011-10-01 | 2015-02-12 |
| TTP607 in Refractory Solid Malignancies TTP607 - Advanced Cancers, Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2010-03-01 | 2012-07-31 | |
| Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA) TTP889, Placebo - Coagulation | Phase 2 | Terminated | vTv Therapeutics | 2 | 2009-06-01 | 2011-06-27 |
| Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss TTP435, Placebo - Obesity | Phase 2 | Completed | vTv Therapeutics | 100 | 2009-02-01 | 2011-06-27 |
| Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial) TTP889 - Venous Thromboembolism, Embolism and Thrombosis | Phase 2 | Completed | vTv Therapeutics | 300 | 2005-01-01 | 2009-06-03 |
Alzheimer Disease (4) · Diabetes Mellitus, Type 2 (4) · Diabetes Mellitus, Type 1 (3) · Embolism (1) · Embolism and Thrombosis (1) · Heart Diseases (1) · Heart Failure (1) · Hip Fractures (1) · Lymphoma (1) · Obesity (1) · Thrombosis (1) · Venous Thromboembolism (1) · Venous Thrombosis (1) · Weight Loss (1)
TTP399 (4) · azeliragon (3) · BID protein, human (1) · Sitagliptin Phosphate (1)
United States (13) · Canada (4) · Australia (1) · Czechia (1) · Denmark (1) · Ireland (1) · New Zealand (1) · Norway (1) · Puerto Rico (1) · South Africa (1) · Sweden (1) · United Kingdom (1)
Carmen Valcarce, Ph.D. (2) · Aaron Burstein, Pharm.D. (1) · Aaron H Burstein, PharmD (1) · Alan Moskowitz, MD (1) · Ann Gooch, Ph.D. (1) · Bengt I Eriksson, MD (1) · David P Ward, MD (1) · James Wamsley, MD (1) · Jennifer Freeman, Ph.D. (1) · Jennifer J. Wheler, MD (1) · Maria Alba, MD (1) · Robert Hernandez, Ph.D. (1) · Stephanie Gustavson, Ph.D. (1) · Thomas Strack, MD (1) · Yoshifumi Naka, MD, PhD (1)